Abstract
Intro: Anatomical abnormality associated with severe developmental dysplasia of the hip presents technical difficulties at THR. Patients often present at a younger age and may have had previous surgery.
We report the difficulties encountered during surgery, and the long term results of patients who had Crowe 3 or 4 DDH and a technically difficult primary hip arthroplasty using the modular S-ROM stem.
Method: 28 patients were entered into the prospective trial. The average age of the patient at surgery was 45 (range 23–74 years). All patients underwent surgery by the senior author using the S-ROM femoral stem. They were followed up for an average of 10 years (range 5–16 years), clinical scores recorded by a clinician other than the surgeon and radiographs were examined by an independent radiologist.
Results: 21 patients required a significant autologous bone graft, one patient had a large allograft and six patients required femoral shortening at the time of their THR.
4 patients had a technical complication during surgery. The average pre-op Harris Hip Score was 37, at 5 years it was 83, and at 10 years 81. The SF12 measure of physical and mental wellbeing was 43.90 physical/54.48 mental at 5 years, and 41.64 physical/54.03 mental at 10 years. The WOMAC average score (the lower the score the better the outcome) was 27 at 5 years and 23 at 10 years.
None of the S-ROM stems had been revised, 2 hips had undergone acetabular revision and one hip had a liner exchange. None of the S-ROM stems were loose at latest follow-up. Four hips had osteolysis in Gruen zone 1, one hip had osteolysis in zone 7, and one hip had osteolysis in zone 1 and 7. There was no evidence of osteolysis around or distal to the sleeve.
Conclusion: The S-ROM stem used in primary THR shows excellent results at 10 years in patients with anatomical abnormality related to severe DDH.
S-ROM stem/sleeve modularity allows femoral component anteversion independent of the position of best fit in the proximal femur, and helps overcome the technical difficulty in these patients.
Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org